Sector: Healthcare|Industry: Health Information Services|Market Cap: $11.83B|Employees: 20K
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
Total net sales increased by 3.9% to $2,161 million for the three months ended June 30, 2025, compared to $2,081 million in the prior year, with organic growth of 2.8%. For the six months, total net sales grew 3.3% to $4,231 million, with organic growth of 3.5%, although currency impact was a slight negative of (0.2)% for the six-month period.
Operating income decreased by 12.3% to $214 million for the three months ended June 30, 2025, and a substantial 41.3% to $367 million for the six months, compared to $244 million and $625 million respectively in the prior year. This decline is largely attributed to higher SG&A costs associated with separation activities from 3M and increased cost of product due to transition manufacturing agreements.
Net cash provided by operating activities significantly decreased to $198 million for the six months ended June 30, 2025, from $797 million in the prior year. This substantial reduction is primarily due to higher year-on-year interest payments on debt, standalone company tax payments, increased annual incentive compensation, and lower net income.